Page last updated: 2024-12-07

dipin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dipin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID96563
CHEMBL ID513619
SCHEMBL ID1413085
MeSH IDM0050787

Synonyms (39)

Synonym
piperazine, 1,4-bis(bis(1-aziridinyl)phosphinyl)-
ai3-50107
tetra-ethyleneimidepiperazine-n,n'-diphosphoric acid
1,4-piperazinediylbis(bis(1-aziridinyl)phosphine oxide)
ent-50107
nsc 80096
phosphine oxide, 1,4-piperazinediylbis(bis(1-aziridinyl)-
1,4-bis(bis-(1-aziridinyl)phosphinyl)piperazine
brn 0629375
1,n'-diethylene phosphamide)piperazine
738-99-8
phosphine oxide,4-piperazinediylbis[bis(1-aziridinyl)-
nsc80096
dipin
1,4-piperazinediylbis[bis(1-aziridinyl)phosphine oxide]
dipine
nsc-80096
wln: t6n dntj apo&- at3ntj&- at3ntj& dpo&- at3ntj&- at3ntj
piperazine,4-bis[bis(1-aziridinyl)phosphinyl]-
1,4-bis[bis(aziridin-1-yl)phosphoryl]piperazine
piperazine, 1,4-bis[bis(1-aziridinyl)phosphinyl]-
1,4-bis(n,n'-diethylene phosphamide)piperazine
1,4-bis(di(1-aziridinyl)phosphoryl)piperazine
phosphine oxide, 1,4-piperazinediylbis[bis(1-aziridinyl)-
NCIOPEN2_009102
STL061072
CHEMBL513619
AKOS003625120
1,4-bis[bis(1-aziridinyl)phosphoryl]piperazine
1,4-bis[bis(aziridin-1-yl)phosphoroso]piperazine
l16knk08vm ,
unii-l16knk08vm
dipin [mi]
phosphineoxide, 1,4-piperazinediylbis(bis(1-aziridinyl)-
DTXSID50224219
SCHEMBL1413085
Q4162033
piperazine-1,4-diylbis(di(aziridin-1-yl)phosphine oxide)
piperazine-1,4-diylbis(di(aziridin-1-yl)phosphineoxide)

Research Excerpts

Treatment

Dipin treatment resulted in cell-cycle arrest at the G2/M boundary without affecting G0/G1 and G1/S transitions. The Dipin treatment caused irreversible damage and gradual death of hepatocytes by necrosis and apoptosis.

ExcerptReferenceRelevance
"In Dipin-treated animals 3H-TdR pulse labelled nuclei appeared 22 h after the partial hepatectomy, followed by a rapid rise in labelling index to a very high level between 43-54 h, and then by a gradual decline to 72 h."( Kinetics of cellular proliferation in regenerating mouse liver pretreated with the alkylating drug dipin.
Brodsky, WY; Chernov, VA; Faktor, VM; Sokolova, AS; Uryvaeva, IV, 1980
)
0.99
"The Dipin treatment resulted in irreversible damage and gradual death of hepatocytes by necrosis and apoptosis."( Origin and fate of oval cells in dipin-induced hepatocarcinogenesis in the mouse.
Factor, VM; Radaeva, SA; Thorgeirsson, SS, 1994
)
1.05
"Dipin treatment resulted in cell-cycle arrest at the G2/M boundary without affecting G0/G1 and G1/S transitions."( Regulation of cyclin G1 during murine hepatic regeneration following Dipin-induced DNA damage.
Factor, VM; Jensen, MR; Thorgeirsson, SS, 1998
)
1.26

Compound-Compound Interactions

ExcerptReferenceRelevance
"Rubomycin or dipin in combination with diacarb had higher toxicity and antitumor activity as compared to administration of the cytostatic agents alone to mice with transplanted lymphosarcoma, strain L10-1."( [Toxicity and antitumor activity of the antibiotic rubomycin and dipin in combination with diuretics (diacarb)].
Stepanova, ES, 1976
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID409958Inhibition of bovine brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409960Inhibition of bovine brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (55.88)18.7374
1990's12 (35.29)18.2507
2000's3 (8.82)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 61.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index61.74 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.10 (4.65)
Search Engine Demand Index100.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (61.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (1.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other53 (98.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]